Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine
Identificadores
URI: http://hdl.handle.net/20.500.12020/729ISSN: 0176-3679
DOI: 10.1055/s-0031-1279728
Autor/es
Molina Martín, Juan de Dios; Toledo-Romero, F.; López-Rodríguez, E.; Amorón Díaz, M.; Lerma-Carrillo, I.; [et al.]Fecha
2011-03-21Tipo de documento
articleResumen
The association of antipsychotics
is a widespread therapeutic resource in clinical
practice. The purpose of the present work was to
evaluate the effi cacy and safety of amisulpride
augmentation in patients responding at least
partially to olanzapine.
Methods: In this observational 3-months
open-label investigation, we evaluated the eff ectiveness
of the addition of amisulpride to 49
subjects, after having scored at least 25 on the
brief psychiatric rating scale (BPRS) following
olanzapine monotherapy for 6 weeks. Patients
were assessed at baseline, 1 and 3 months using
the BPRS, the clinical global impression severity of
illness (CGI-S) scale and the Udvalg for Kliniske
Undersogelser side eff ect rating scale (UKU).